



Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020)

M. A. Pfaller,^{a,b}  M. D. Huband,^a P. R. Rhomberg,^a P. A. Bien,^c  M. Castanheira^a

^aJMI Laboratories, North Liberty, Iowa, USA

^bUniversity of Iowa, Iowa City, Iowa, USA

^cPfizer Inc., New York, New York, USA

ABSTRACT We evaluated the *in vitro* activity of manogepix and comparator agents against 1,435 contemporary fungal isolates collected worldwide from 73 medical centers in North America, Europe, the Asia-Pacific region, and Latin America during 2020. Of the isolates tested, 74.7% were *Candida* spp.; 3.7% were non-*Candida* yeasts, including 27 *Cryptococcus neoformans* var. *grubii* (1.9%); 17.1% were *Aspergillus* spp.; and 4.5% were other molds. All fungal isolates were tested by reference broth microdilution according to CLSI methods. Based on MIC₉₀ values, manogepix (MIC₅₀/MIC₉₀, 0.008/0.06 mg/liter) was 16- to 64-fold more active than anidulafungin, micafungin, and fluconazole against *Candida* spp. isolates and the most active agent tested. Similarly, manogepix (MIC₅₀/MIC₉₀, 0.5/1 mg/liter) was ≥8-fold more active than anidulafungin, micafungin, and fluconazole against *C. neoformans* var. *grubii*. Based on minimum effective concentration for 90% of the isolates tested (MEC₉₀) and MIC₉₀ values, manogepix (MEC₉₀, 0.03 mg/liter) was 16- to 64-fold more potent than itraconazole, posaconazole, and voriconazole (MIC_{90S}, 0.5 to 2 mg/liter) against 246 *Aspergillus* spp. isolates. *Aspergillus fumigatus* isolates exhibited a wild-type (WT) phenotype for the mold-active triazoles, including itraconazole (87.0% WT) and voriconazole (96.4% WT). Manogepix was highly active against uncommon species of *Candida*, non-*Candida* yeasts, and rare molds, including 11 isolates of *Candida auris* (MIC₅₀/MIC₉₀, 0.004/0.015 mg/liter) and 12 isolates of *Scedosporium* spp. (MEC₅₀/MEC₉₀, 0.06/0.12 mg/liter). Additional studies are in progress to evaluate the clinical utility of the manogepix prodrug fosmanogepix in difficult-to-treat resistant fungal infections.

KEYWORDS APX001, APX001A, Gwt1, antifungal, fosmanogepix, manogepix

Invasive fungal infections (IFI) due to opportunistic fungal pathogens pose a major stumbling block to the successful implementation of advances in medical therapy (1, 2). Whereas the majority of IFI and associated deaths are due to *Aspergillus*, *Candida*, and *Cryptococcus* species, other less common opportunistic yeasts and molds increasingly are emerging as deadly antifungal resistant pathogens (1–6). Accordingly, new antifungal therapies that act through novel mechanisms of action are needed to control the high mortality of IFIs and combat the emergence of resistance to existing treatment regimens. Several antifungal agents with the potential to address the emergence of multidrug-resistant yeasts and molds (i.e., resistant to at least 2 different classes of antifungal agents) are presently in clinical development (7–13).

Among the more recent, systemically active antifungal agents, manogepix (formerly APX001A and E1210) is notable for its unique mechanism of action. Manogepix targets the highly conserved fungal enzyme Gwt1 (14). Inhibiting Gwt1 blocks the inositol acylation step during the synthesis of glycosylphosphatidylinositol-anchored proteins of

Copyright © 2022 Pfaller et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to M. D. Huband, michael-huband@jmilabs.com.

The authors declare a conflict of interest. JMI Laboratories contracted to perform services in 2020 for Achaogen, Inc., Albany College of Pharmacy and Health Sciences, Allegra Therapeutics, Allergan, AmpliPhi Biosciences Corp., Amicrobe Advanced Biomaterials, Amlyx, Antabio, American Proficiency Institute, Arietis Corp., Arixa Pharmaceuticals, Inc., Astellas Pharma Inc., Athelas, Basilea Pharmaceutica Ltd., Bayer AG, Becton, Dickinson and Company, bioMerieux SA, Boston Pharmaceuticals, Bugworks Research Inc., CEM-102 Pharmaceuticals, Cepheid, Cidara Therapeutics, Inc., CorMedix Inc., DePuy Synthes, Destiny Pharma, Discuva Ltd., Dr. Falk Pharma GmbH, Emery Pharma, Entasis Therapeutics, Eurofarma Laboratorios SA, US Food and Drug Administration, Fox Chase Chemical Diversity Center, Inc., Gateway Pharmaceutical LLC, GenePOC Inc., Geom Therapeutics, Inc., GlaxoSmithKline plc, Harvard University, Helperby, HiMedia Laboratories, F. Hoffmann-La Roche Ltd., ICON plc, Idorsia Pharmaceuticals Ltd., Iterum Therapeutics plc, Laboratory Specialists, Inc., Melinta Therapeutics, Inc., Merck & Co., Inc., Microchem Laboratory, Micromyx, MicuRx Pharmaceuticals, Inc., Mutabilis Co., Nabriva Therapeutics plc, NAEJA-RGM, Novartis AG, Oxoid Ltd., Paratek Pharmaceuticals, Inc., Pfizer, Inc., Polyphor Ltd., Pharmaceutical Product Development, LLC, Prokaryotics Inc., Qpex Biopharma, Inc., Roivant Sciences, Ltd., Safeguard Biosystems, Scynexis, Inc., SeLux Diagnostics, Inc., Shionogi and Co., Ltd., SinSa Labs, Spero Therapeutics, Summit Pharmaceuticals International Corp., Synlogic, T2 Biosystems, Inc., Taisho Pharmaceutical Co., Ltd., TenNor Therapeutics Ltd., Tetrphase Pharmaceuticals, Theravance Biopharma, University of Colorado, University of Southern California-San Diego, University of North Texas Health Science Center, VenatoRx Pharmaceuticals, Inc., Viosera Therapeutics, Vyome Therapeutics Inc., Wockhardt, Yukon Pharmaceuticals, Inc., Zai Lab, Zavante Therapeutics, Inc. There are no speakers' bureaus or stock options to declare. P. A. Bien is an employee of Pfizer, Inc.

Received 28 July 2022

Returned for modification 20 August 2022

Accepted 14 September 2022

Published 26 October 2022

the fungal cell wall. This inhibition compromises cell wall integrity, biofilm formation, and germ tube formation, resulting in severe fungal growth defects (14). Manogepix demonstrates broad-spectrum antifungal activity against common species of *Candida*, *Cryptococcus neoformans*, *Cryptococcus gattii*, *Aspergillus* spp., multidrug-resistant strains such as *Candida auris*, and rare molds, which are often difficult to treat due to their inherent resistance to most antifungals, including *Fusarium* spp., *Scedosporium* spp., and *Lomentospora (Scedosporium) prolificans* (12, 13, 15–22).

In the present study, we utilized SENTRY Antimicrobial Surveillance Program data from 2020 to examine the *in vitro* activity of manogepix as well as its comparators, anidulafungin, micafungin, fluconazole, itraconazole, posaconazole, voriconazole, and amphotericin B, against 1,435 contemporary clinical fungal isolates from bloodstream infections (BSIs), respiratory tract infections (RTIs), skin and skin structure infections (SSSIs), urinary tract infections (UTIs), intra-abdominal infections (IAs), and other infection types. The fungal isolates were collected from 73 medical centers located in North America (568 isolates from 29 medical centers), Europe (566 isolates from 28 medical centers), the Asia-Pacific region (182 isolates from 10 medical centers), and Latin America (119 isolates from 6 medical centers). These data expand on our previous reports from 2017 (20) and 2018–2019 (12), allowing examination of temporal trends in fungal species distribution and antifungal susceptibility results as well as providing a robust MIC database for eventual determination of both epidemiological cutoff values (ECVs) and clinical breakpoints (CBPs) for manogepix and other antifungal agents and a variety of fungal species.

RESULTS

The frequency distributions and cumulative percent inhibition data for manogepix against the species and organism groups tested are listed in Table 1. All fungal species containing ≥ 10 isolates were analyzed separately. Manogepix and comparator agent susceptibility results for fungal species with fewer than 10 isolates are listed in Tables S1 and S2 in the supplemental material.

Of the 1,435 fungal clinical isolates tested, 1,072 (74.7%) were *Candida* spp.; 53 (3.7%) were non-*Candida* yeasts, including 27 *Cryptococcus neoformans* var. *grubii* (1.9%); 246 (17.1%) were *Aspergillus* spp.; and 64 (4.5%) were other molds (Table 1; Tables S1 and S2). The geographic distribution of fungal isolates was 39.6% from North America, 39.4% from Europe, 12.7% from the Asia-Pacific region, and 8.3% from Latin America (data not shown).

Activity of manogepix against *Candida* spp. and *Cryptococcus neoformans* var. *grubii* isolates. Among the 10 species of *Candida* in Table 1, manogepix was most active against *Candida albicans* and *Candida dubliniensis* (MIC_{90} , 0.008 mg/liter) and least active against *Candida kefyr* (MIC_{90} , 1 mg/liter) and *Candida krusei* (MIC_{90} , >8 mg/liter). *C. krusei* (MIC_{50}/MIC_{90} , $>8/>8$ mg/liter) is considered intrinsically resistant to manogepix (13). All *C. auris* isolates ($n = 11$) were inhibited by ≤ 0.03 mg/liter manogepix. Overall, 93.8% of the 1,072 *Candida* spp. isolates tested were inhibited by ≤ 0.06 mg/liter manogepix and 95.5% were inhibited by ≤ 0.25 mg/liter manogepix (Table 1). Manogepix had an MIC distribution spanning six 2-fold dilution steps (range, 0.03 to 1 mg/liter) and did not have a clear mode against 27 *C. neoformans* var. *grubii* isolates (MIC_{50}/MIC_{90} , 0.5/1 mg/liter; 100.0% inhibited at ≤ 1 mg/liter) (Table 1).

Determination of the wild-type manogepix MIC distribution for *Candida* spp. The upper limit of the manogepix wild-type MIC distribution (WT-UL, two 2-fold dilutions higher than the modal MIC value) for each species was determined by compiling the data from the 2017 (20), 2018–2019 (12), and 2020 (present study) SENTRY Surveillance Program surveys to provide a robust set of values representing the WT MIC distributions as determined by CLSI methods (Table 2). Importantly, the modal manogepix MIC value for each species was within 1 dilution step, as were the MIC_{50}/MIC_{90} values, irrespective of the individual survey. The similarity of these values ensured comparable MIC distributions across the three surveys. The WT-UL cutoff value was determined for each species by using the combined 2017 to 2020 MIC distribution (Table 2).

TABLE 1 Manogepix frequency and cumulative percent inhibition against the main organisms and organism groups tested using the CLSI broth microdilution method

Organism group or organism (no. of isolates)	No. (cumulative %) of isolates inhibited at MIC or MEC (mg/liter) of ^a :													MIC ₅₀	MIC ₉₀	
	≤0.002	0.004	0.008	0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8			> ^b
<i>Candida</i> spp. (1,072)	29 (2.7)	226 (23.8)	313 (53.0)	218 (73.3)	150 (87.3)	69 (93.8)	13 (95.0)	6 (95.5)	2 (95.7)	2 (95.9)	1 (96.0)	1 (96.1)	5 (96.5)	37 (100.0)	0.008	0.06
<i>C. albicans</i> (350)	12 (3.4)	178 (54.3)	152 (97.7)	6 (99.4)	1 (99.7)	0 (99.7)	1 (100.0)								0.004	0.008
<i>C. auris</i> (11)	3 (27.3)	6 (81.8)	0 (81.8)	1 (90.9)	1 (100.0)										0.004	0.015
<i>C. dubliniensis</i> (40)	5 (12.5)	25 (75.0)	10 (100.0)												0.004	0.008
<i>C. glabrata</i> (258)	0 (0.0)	1 (0.4)	20 (8.1)	54 (29.1)	112 (72.5)	62 (96.5)	9 (100.0)								0.03	0.06
<i>C. kefyr</i> (10)					0 (0.0)	1 (10.0)	2 (30.0)	1 (80.0)	2 (100.0)						0.25	1
<i>C. krusei</i> (45)							0 (0.0)	2 (4.4)	0 (4.4)	0 (4.4)	1 (6.7)	5 (17.8)	37 (100.0)		>8	0.06
<i>C. lusitanae</i> (16)			0 (0.0)	5 (31.2)	7 (75.0)	4 (100.0)									0.03	0.06
<i>C. orthopsilosis</i> (12)		0 (0.0)	7 (58.3)	3 (83.3)	2 (100.0)										0.008	0.03
<i>C. parapsilosis</i> (165)	0 (0.0)	4 (2.4)	89 (56.4)	58 (91.5)	13 (99.4)	1 (100.0)									0.008	0.015
<i>C. tropicalis</i> (139)	1 (0.7)	6 (5.0)	30 (26.6)	89 (90.6)	11 (98.6)	1 (99.3)	1 (100.0)								0.015	0.015
Other <i>Candida</i> spp. (24) ^c	8 (33.3)	5 (54.2)	4 (70.8)	2 (79.2)	3 (91.7)	0 (91.7)	0 (91.7)	1 (95.8)	0 (95.8)	1 (100.0)					0.004	0.03
<i>Cryptococcus neoformans</i> var. <i>grubii</i> (27)			0 (0.0)	0 (0.0)	2 (7.4)	5 (25.9)	3 (37.0)	8 (74.1)	7 (100.0)						0.5	1
Other Yeasts (26) ^d	0 (0.0)	0 (0.0)	3 (11.5)	5 (30.8)	7 (57.7)	3 (69.2)	1 (73.1)	1 (76.9)	1 (80.8)	1 (84.6)	0 (84.6)	0 (84.6)	0 (84.6)	4 (100.0)	0.03	>8
<i>Aspergillus</i> spp. (246)	0 (0.0)	7 (2.8)	47 (22.0)	141 (79.3)	45 (97.6)	6 (100.0)									0.015	0.03
<i>A. fumigatus</i> (169)	0 (0.0)	0 (0.0)	20 (11.8)	110 (76.9)	36 (98.2)	3 (100.0)									0.015	0.03
<i>Aspergillus</i> section <i>Flavi</i> (24)		0 (0.0)	0 (0.0)	3 (12.5)	13 (66.7)	5 (87.5)									0.015	0.06
<i>Aspergillus</i> section <i>Nigri</i> (27)	0 (0.0)	6 (22.2)	14 (74.1)	5 (92.6)	2 (100.0)										0.008	0.015
<i>Aspergillus</i> section <i>Terrei</i> (14)	0 (0.0)	1 (7.1)	7 (57.1)	5 (92.9)	1 (100.0)										0.008	0.015
Other <i>Aspergillus</i> spp. (12) ^e		0 (0.0)	3 (25.0)	8 (91.7)	1 (100.0)										0.015	0.015
<i>Scedosporium</i> spp. (12) ^f			0 (0.0)	0 (0.0)	3 (25.0)	7 (83.3)	1 (91.7)	0 (91.7)	1 (100.0)						0.06	0.12
Other molds (52) ^g	6 (11.5)	9 (28.8)	11 (50.0)	8 (65.4)	2 (69.2)	3 (75.0)	0 (75.0)	2 (78.8)	0 (78.8)	2 (82.7)	2 (86.5)	3 (92.3)	1 (94.2)	3 (100.0)	0.008	4

^aThe 24-h MIC recorded for *Candida* spp., 48-h MIC recorded for other yeasts and *C. neoformans* var. *grubii*; 72-h MEC recorded for *Scedosporium* spp., or 48-h MEC recorded for *Aspergillus* spp. and other molds. Numbers in boldface are modal MIC values.

^bGreater than the highest dilution tested.

^cOrganisms (number of isolates) include *Candida bracarensis* (2), *C. duobushaemulonii* (1), *C. fermentati* (2), *C. guilliermondii* (6), *C. haemulonii* (1), *C. inconspicua* (2), *C. nivariensis* (1), *C. pelliculosa* (4), *C. rugosa* (2), *C. spenceri* (1), and *C. utilis* (2).

^dOrganisms (number of isolates) include *Cryptococcus gattii* species complex (1), *C. neoformans* var. *neoformans* (3), *Saprochaete clavata* (3), *Kodamaea ohmeri* (1), *Magnusiomyces capitatus* (1), *Rhodotorula mucilaginosa* (5), *Saccharomyces cerevisiae* (7), *Trichosporon asahii* (4), *T. mycotoxinivorans* (1), and *Yarrowia lipolytica* (1).

^eOrganisms (number of isolates) include *Aspergillus nidulans* (6), *A. nidulans* species complex (2), *A. sclerotiorum* (1), *A. ustus* (1), *A. ustus* species complex (1), and *A. versicolor* (1).

^fOrganisms (number of isolates) include *Scedosporium apiospermum*/*Scedosporium boydii* (9) and *S. aurantiacum* (3).

^gOrganisms (number of isolates) include *Exophiala dermatitidis* (1), *Fusarium incarnatum-equiseti* species complex (1), *F. solani* (2), *F. solani* species complex (5), *Gibberella fujikuroi* species complex (6), *Lichtheimia corymbifera* (1), *Lomentospora prolificans* (4), *Mucor circinelloides* (2), *M. indicus* (1), *Purpuriocillium lilacinum* (2), *P. variotii* (7), *Penicillium citrinum* (1), *P. onobense* (1), *Rasamsonia argillacea* (1), *R. argillacea* species complex (3), *Rhizopus microsporus* group (4), *R. oryzae* (1), *R. oryzae* species complex (1), *Sarocladium kiliense* (1), *Scopulariopsis brevicaulis* (1), unspiciated *Coprinellus* (1), unspiciated *Cunninghamella* (1), unspiciated *Lichtheimia* (1), unspiciated *Paeclomyces* (1), and unspiciated *Trichoderma* (1).

TABLE 2 Summary of manogepix surveillance data as determined by CLSI broth microdilution methods for *Candida* spp. and *Aspergillus* spp. in this and prior studies

Organism	Yr(s)	<i>n</i>	MIC ₅₀ /MIC ₉₀ (mg/liter)	Mode (mg/liter)	WT-UL (mg/liter)	Reference
<i>C. albicans</i>	2017	414	0.008/0.008	0.008	0.03 (100.0%) ^a	Pfaller et al. (20)
	2018–2019	588	0.004/0.008	0.004/0.008 ^b	0.03 (100.0%)	Pfaller et al. (12)
	2020	350	0.004/0.008	0.004/0.008 ^b	0.03 (99.7%)	This study
	2017–2020	1,352	0.004/0.008	0.004/0.008 ^b	0.03 (99.9%)	Overall
<i>C. glabrata</i>	2017	321	0.06/0.12	0.06	0.25 (100.0%)	Pfaller et al. (20)
	2018–2019	460	0.03/0.06	0.03	0.12 (100.0%)	Pfaller et al. (12)
	2020	258	0.03/0.06	0.03	0.12 (100.0%)	This study
	2017–2020	1,039	0.03/0.06	0.03/0.06 ^b	0.25 (100.0%)	Overall
<i>C. parapsilosis</i>	2017	270	0.008/0.015	0.008	0.03 (98.9%)	Pfaller et al. (20)
	2018–2019	321	0.008/0.015	0.008	0.03 (98.4%)	Pfaller et al. (12)
	2020	165	0.008/0.015	0.008	0.03 (99.4%)	This study
	2017–2020	756	0.008/0.015	0.008	0.03 (98.8%)	Overall
<i>C. tropicalis</i>	2017	151	0.015/0.03	0.015	0.06 (100.0%)	Pfaller et al. (20)
	2018–2019	225	0.015/0.015	0.008/0.015 ^b	0.06 (99.6%)	Pfaller et al. (12)
	2020	139	0.015/0.015	0.015	0.06 (99.3%)	This study
	2017–2020	515	0.015/0.03	0.015	0.06 (99.6%)	Overall
<i>C. dubliniensis</i>	2017	49	0.004/0.008	0.004	0.015 (100.0%)	Pfaller et al. (20)
	2018–2019	65	0.004/0.008	0.004	0.015 (98.5%)	Pfaller et al. (12)
	2020	40	0.004/0.008	0.004	0.008 (100.0%)	This study
	2017–2020	154	0.004/0.008	0.004	0.015 (99.4%)	Overall
<i>C. lusitanae</i>	2017	39	0.03/0.12	NM ^c	NA ^d	Pfaller et al. (20)
	2018–2019	52	0.03/0.06	0.03	0.12 (98.1%)	Pfaller et al. (12)
	2020	16	0.03/0.06	0.03	0.06 (100.0%)	This study
	2017–2020	107	0.03/0.12	0.03	0.12 (97.2%)	Overall
<i>C. kefyr</i>	2017	13	0.12/0.5	0.06/0.12 ^b	0.5 (100.0%)	Pfaller et al. (20)
	2018–2019	28	0.12/0.25	0.12/0.25 ^b	0.5 (100.0%)	Pfaller et al. (12)
	2020	10	0.25/1	0.25	1 (100.0%)	This study
	2017–2020	51	0.12/0.5	0.12/0.25 ^b	1 (100.0%)	Overall
<i>A. fumigatus</i>	2017	182	0.015/0.03	0.015	0.06 (100.0%)	Pfaller et al. (20)
	2018–2019	397	0.015/0.03	0.015	0.06 (100.0%)	Pfaller et al. (12)
	2020	169	0.015/0.03	0.015	0.06 (100.0%)	This study
	2017–2020	748	0.015/0.03	0.015	0.06 (100.0%)	Overall
<i>Aspergillus</i> section Flavi	2017	18	0.015/0.03	0.03	0.06 (100.0%)	Pfaller et al. (20)
	2018–2019	73	0.015/0.03	0.015	0.06 (100.0%)	Pfaller et al. (12)
	2020	24	0.015/0.06	0.015	0.06 (100.0%)	This study
	2017–2020	115	0.015/0.03	0.015	0.06 (100.0%)	Overall
<i>Aspergillus</i> section Nigri	2017	23	≤0.008/0.015	≤0.008	0.03 (100.0%)	Pfaller et al. (20)
	2018–2019	67	0.008/0.015	0.015	0.03 (100.0%)	Pfaller et al. (12)
	2020	27	0.008/0.015	0.008	0.03 (100.0%)	This study
	2017–2020	117	≤0.008/0.015	≤0.008	0.03 (100.0%)	Overall
<i>Aspergillus</i> section Terrei	2017	10	0.015/0.03	0.015	0.03 (100.0%)	Pfaller et al. (20)
	2018–2019	19	0.008/0.03	0.008	0.03 (100.0%)	Pfaller et al. (12)
	2020	14	0.008/0.015	0.008	0.03 (100.0%)	This study
	2017–2020	43	0.015/0.03	0.015	0.03 (100.0%)	Overall

^aPercent of isolates encompassed by WT-UL.^bBimodal MIC distribution.^cNM, no mode.^dNA, not applicable.

The upper limit of the WT MIC distribution for manogepix was 0.015 mg/liter for *C. dubliniensis* (99.4% WT; 153/154 isolates), 0.03 mg/liter for *C. albicans* (99.9% WT; 1,351/1,352 isolates), 0.03 mg/liter for *Candida parapsilosis* (98.8% WT; 747/756 isolates), 0.06 mg/liter for *Candida tropicalis* (99.6% WT; 513/515 isolates), 0.25 mg/liter for *Candida glabrata* (100.0% WT; 1,039/1,039 isolates), 0.12 mg/liter for *Candida lusitanae* (97.2% WT; 104/107 isolates), and 1 mg/liter for *C. kefyr* (100.0% WT; 51/51 isolates) (Table 2). The WT-UL MIC for 23 *C. auris* isolates could not be determined due to the lack of a clear mode (data not shown).

***In vitro* activity of manogepix and comparators against *Candida* spp. and *Cryptococcus neoformans* var. *grubii* isolates.** Of the 350 *C. albicans* isolates tested, all but 1 were inhibited by ≤0.03 mg/liter manogepix (99.7% WT; MIC₅₀/MIC₉₀

0.004/0.008 mg/liter), and echinocandin susceptibility was 99.7% for micafungin and 100.0% for anidulafungin using current CLSI M27M44S (23) breakpoint interpretive criteria (Tables 1 and 3). All but 3 *C. albicans* isolates were susceptible to fluconazole (99.1%), 99.7% were susceptible to voriconazole, and 97.4% were WT (MIC, \leq 0.06 mg/liter) to posaconazole (Table 3). A single *C. albicans* isolate for which the echinocandin MIC values were greater than the ECV was screened for the presence of *fk*s hot spot (HS) mutations (Table 4). This isolate from Taiwan displayed amino acid alteration *fk*s1 HS1 S645P (an S-to-P change at position 645) (Table 4). Its corresponding manogepix MIC value was 0.008 mg/liter (Table 4).

All (100%) of the 258 *C. glabrata* isolates tested were inhibited by manogepix (MIC₅₀/MIC₉₀, 0.03/0.06 mg/liter) at the WT-UL MIC cutoff value of \leq 0.25 mg/liter (Tables 1 to 3). Micafungin (MIC₅₀/MIC₉₀, 0.015/0.03 mg/liter) and anidulafungin (MIC₅₀/MIC₉₀, 0.12/0.12 mg/liter) susceptibilities were 97.3% and 96.5%, respectively, at the current CLSI breakpoints for these compounds (23). Seven *C. glabrata* isolates displayed echinocandin MIC values greater than the CLSI ECV and were screened for the presence of *fk*s HS mutations. Of these isolates, 6 harbored amino acid alterations (Table 4). The most common substitution was *fk*s2 HS1 S663P (3 isolates). Two isolates carried mutations in *fk*s1 (HS1; D632E or S629P), and one carried a mutation in *fk*s2 (HS1; R665G). The 6 echinocandin nonsusceptible isolates with *fk*s mutations, all of which were resistant (R) to micafungin, were from the United States and represented 5.3% of North American *C. glabrata* isolates (Table 4). Manogepix MIC values against these echinocandin-R *C. glabrata* isolates ranged from 0.008 to 0.12 mg/liter (all \leq WT-UL) (Table 4). Resistance of *C. glabrata* isolates to fluconazole was 5.0% (Table 3). A total of 3.9% and 9.3% of *C. glabrata* isolates were non-wild type (NWT) to posaconazole and voriconazole, respectively, using the ECVs published by CLSI (24) (Table 3).

Manogepix (MIC₅₀/MIC₉₀, 0.008/0.015 mg/liter) inhibited 99.4% of 165 *C. parapsilosis* isolates at the WT-UL of \leq 0.03 mg/liter (Tables 1 to 3). Micafungin (MIC₅₀/MIC₉₀, 1/1 mg/liter) and anidulafungin (MIC₅₀/MIC₉₀, 2/2 mg/liter) susceptibilities were 100.0% and 92.1%, respectively, at the current CLSI *C. parapsilosis* breakpoints for these compounds (Table 3). A total of 7.9% of *C. parapsilosis* isolates were intermediate in susceptibility to anidulafungin (MIC, 4 mg/liter) (Table 3). Susceptibility of *C. parapsilosis* isolates to fluconazole and voriconazole was 92.1% and 94.5%, respectively, using current CLSI breakpoint interpretive criteria (Table 3). All (100.0%) *C. parapsilosis* isolates were WT to posaconazole (Table 3). The other member of the *C. parapsilosis* species complex (SC), *Candida orthopsilosis*, tended to be slightly more susceptible than *C. parapsilosis sensu stricto* to the echinocandins and was equally susceptible to manogepix and less susceptible to the azoles (Table 3).

Manogepix (MIC₅₀/MIC₉₀, 0.015/0.015 mg/liter), anidulafungin (MIC₅₀/MIC₉₀, 0.03/0.06 mg/liter; 100.0% susceptible), and micafungin (MIC₅₀/MIC₉₀, 0.03/0.03 mg/liter; 100.0% susceptible) displayed comparable activities against 139 *C. tropicalis* isolates (Tables 1 and 3). All but 1 *C. tropicalis* isolate was WT for manogepix (WT-UL, 0.06 mg/liter; 99.3% WT) (Table 3). Susceptibility of *C. tropicalis* isolates to fluconazole and voriconazole were 95.0% and 95.7%, respectively, according to current CLSI breakpoint interpretive criteria.

Manogepix MIC₅₀/MIC₉₀ values were $>8/>8$ mg/liter against the 45 *C. krusei* isolates tested (Table 1). All (100%) *C. krusei* isolates were susceptible to anidulafungin and micafungin, 97.8% were susceptible to voriconazole, and all were WT to posaconazole (data not shown).

By comparison with the common species of *Candida* noted above, manogepix was more active against *C. dubliniensis* (MIC₅₀/MIC₉₀, 0.004/0.008 mg/liter; 100.0% WT), *C. lusitanae* (MIC₅₀/MIC₉₀, 0.03/0.06 mg/liter; 100.0% WT), and *C. auris* (MIC₅₀/MIC₉₀, 0.004/0.015 mg/liter) isolates and less active against *C. kefyr* (MIC₅₀/MIC₉₀, 0.25/1 mg/liter; 100.0% WT) isolates (Tables 1 and 3). All isolates of *C. dubliniensis* and *C. lusitanae* were classified as WT to anidulafungin (CLSI ECV, 0.12 and 1 mg/liter, respectively) and micafungin (CLSI ECV, 0.12 and 0.5 mg/liter, respectively) (Table 3). One (6.2%) *C. lusitanae* isolate and no (0.0%) *C. dubliniensis* isolates were NWT to fluconazole (Table 3). The 11 *C. auris* isolates consisted of 3 isolates from the United States (2 from New York and 1 from Texas), 5 isolates from

TABLE 3 *In vitro* activity of manogepix and comparator agents tested against *Candida* spp. and *C. neoformans* isolates

Organism (no. tested) and antifungal agent	MIC data (mg/liter)			CLSI CBP ^a			CLSI ECV ^a	
	MIC ₅₀	MIC ₉₀	Range	% S	% I/SDD	% R	% WT	% NWT
<i>C. albicans</i> (350)								
Manogepix	0.004	0.008	≤0.002–0.12				99.7	0.3
Anidulafungin	0.03	0.06	≤0.002–0.25	100.0	0.0	0.0	99.7	0.3
Micafungin	0.015	0.015	≤0.002–2	99.7	0.0	0.3	99.1	0.9
Fluconazole	0.12	0.25	≤0.008–>128	99.1	0.3	0.6 ^b	97.1	2.9
Posaconazole	0.03	0.06	0.004–>8				97.4	2.6
Voriconazole	0.004	0.015	≤0.002–>8	99.7	0.0	0.3	98.6	1.4
Amphotericin B	0.5	0.5	0.06–1				100.0	0.0
<i>C. glabrata</i> (258)								
Manogepix	0.03	0.06	0.004–0.12				100.0	0.0
Anidulafungin	0.12	0.12	0.03–4	96.5	1.2	2.3	97.7	2.3
Micafungin	0.015	0.03	0.008–4	97.3	0.0	2.7	96.9	3.1
Fluconazole	4	8	0.12–>128		95.0	5.0 ^c	90.3	9.7
Posaconazole	0.5	1	0.12–>8				96.1	3.9
Voriconazole	0.12	0.25	0.015–8				90.7	9.3
Amphotericin B	1	1	0.25–1				100.0	0.0
<i>C. parapsilosis</i> (165)								
Manogepix	0.008	0.015	0.004–0.06				99.4	0.6
Anidulafungin	2	2	0.5–4	92.1	7.9	0.0	100.0	0.0
Micafungin	1	1	0.25–2	100.0	0.0	0.0	100.0	0.0
Fluconazole	0.5	2	0.12–128	92.1	0.0	7.9 ^b	92.1	7.9
Posaconazole	0.06	0.12	0.015–0.25				100.0	0.0
Voriconazole	0.008	0.03	≤0.002–1	94.5	3.6	1.8	91.5	8.5
Amphotericin B	0.5	1	0.25–1				100.0	0.0
<i>C. tropicalis</i> (139)								
Manogepix	0.015	0.015	≤0.002–0.12				99.3	0.7
Anidulafungin	0.03	0.06	0.008–0.25	100.0	0.0	0.0	100.0	0.0
Micafungin	0.03	0.03	0.008–0.06	100.0	0.0	0.0	100.0	0.0
Fluconazole	0.5	1	0.06–>128	95.0	1.4	3.6 ^b	94.2	5.8
Posaconazole	0.06	0.12	0.015–>8				94.2	5.8
Voriconazole	0.03	0.06	0.004–>8	95.7	1.4	2.9	95.7	4.3
Amphotericin B	0.5	1	0.25–1				100.0	0.0
<i>C. auris</i> (11)								
Manogepix	0.004	0.015	≤0.002–0.03					
Anidulafungin	0.25	0.25	0.12–0.25	100.0		0.0 ^d		
Micafungin	0.12	0.12	0.06–0.12	100.0		0.0 ^d		
Fluconazole	32	>128	2–>128	36.4		63.6 ^d		
Posaconazole	0.06	0.5	0.03–0.5					
Voriconazole	0.12	1	0.015–1					
Amphotericin B	1	2	1–2	72.7		27.3 ^d		
<i>C. dubliniensis</i> (40)								
Manogepix	0.004	0.008	≤0.002–0.008				100.0	0.0
Anidulafungin	0.06	0.12	0.015–0.12				100.0	0.0
Micafungin	0.015	0.03	0.008–0.06				100.0	0.0
Fluconazole	0.12	0.25	0.06–0.25				100.0	0.0
Posaconazole	0.03	0.06	0.015–0.06				100.0	0.0
Voriconazole	0.004	0.008	≤0.002–0.015					
Amphotericin B	0.25	0.5	0.12–1				97.5	2.5
<i>C. kefyr</i> (10)								
Manogepix	0.25	1	0.06–1				100.0	0.0
Anidulafungin	0.06	0.12	0.06–0.25				100.0	0.0
Micafungin	0.06	0.12	0.03–0.12				100.0	0.0
Fluconazole	0.5	0.5	0.06–0.5				100.0	0.0
Posaconazole	0.12	0.12	0.06–0.25				100.0	0.0
Voriconazole	0.008	0.008	≤0.002–0.015					
Amphotericin B	1	1	0.5–1				100.0	0.0

(Continued on next page)

TABLE 3 (Continued)

Organism (no. tested) and antifungal agent	MIC data (mg/liter)			CLSI CBP ^a			CLSI ECV ^a	
	MIC ₅₀	MIC ₉₀	Range	% S	% I/SDD	% R	% WT	% NWT
<i>C. lusitanae</i> (16)								
Manogepix	0.03	0.06	0.015–0.06				100.0	0.0
Anidulafungin	0.5	1	0.12–1				100.0	0.0
Micafungin	0.12	0.25	0.06–0.25				100.0	0.0
Fluconazole	0.5	1	0.12–4				93.8	6.2
Posaconazole	0.06	0.12	0.03–0.12				87.5	12.5
Voriconazole	0.008	0.015	0.004–0.03					
Amphotericin B	0.5	0.5	0.25–1				100.0	0.0 ^e
<i>C. orthopsilosis</i> (12)								
Manogepix	0.008	0.03	0.008–0.03					
Anidulafungin	0.5	1	0.25–1				100.0	0.0
Micafungin	0.25	0.5	0.12–0.5				100.0	0.0
Fluconazole	0.5	128	0.5–>128				83.3	16.7
Posaconazole	0.06	0.5	0.06–0.5				83.3	16.7
Voriconazole	0.015	4	0.008–8				83.3	16.7
Amphotericin B	0.5	0.5	0.25–0.5				100.0	0.0
<i>Cryptococcus neoformans</i> var. <i>grubii</i> (27)								
Manogepix	0.5	1	0.03–1					
Anidulafungin	>4	>4	>4–>4					
Micafungin	>4	>4	>4–>4					
Fluconazole	4	8	0.5–8				100.0	0.0
Posaconazole	0.12	0.25	0.03–0.25				100.0	0.0
Voriconazole	0.06	0.06	0.008–0.12				100.0	0.0
Amphotericin B	0.5	1	0.5–1				51.9	48.1

^aClinical breakpoint (CBP) MIC criteria were those published in CLSI document M27M44S (23) and M38M51S (34). ECV criteria were those published in CLSI document M57S (24). The WT-UL was used in place of ECV for manogepix (see Table 2).

^bIntermediate was interpreted as susceptible/dose dependent.

^cNonresistant was interpreted as susceptible/dose dependent.

^dBreakpoints for this organism originated from the CDC tentative MIC breakpoints published at <https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.html>.

^e*Candida lusitanae* is not intrinsically resistant to amphotericin B. However, *C. lusitanae* may develop resistance to amphotericin B *in vivo* during therapy.

Greece, and 3 isolates from Latin America (Panama). All *C. auris* isolates were inhibited by ≤0.03 mg/liter manogepix, and all were susceptible to anidulafungin and micafungin using the CDC tentative MIC breakpoints (Table 3). Of these 11 *C. auris* isolates, the isolates from New York and Greece were fluconazole resistant, and those obtained from Panama and Texas were fluconazole susceptible.

All 27 *C. neoformans* var. *grubii* isolates were inhibited by ≤2 mg/liter manogepix (MIC₅₀/MIC₉₀, 0.5/1 mg/liter) (Tables 1 and 3). In addition, 100.0% of *C. neoformans* var. *grubii* isolates displayed WT MIC values for voriconazole, fluconazole, and

TABLE 4 Summary of FKS alterations detected in *Candida* sp. isolates as part of the 2020 international surveillance program

Country	Organism	MIC (mg/liter) ^a			1,3-β-D-glucan synthase alteration			
		Manogepix	Anidulafungin	Micafungin	<i>fk1</i> HS1	<i>fk1</i> HS2	<i>fk2</i> HS1	<i>fk2</i> HS2
Taiwan	<i>C. albicans</i>	0.008	0.25 (S)	2 (R)	S645P	WT ^b	NT ^c	NT
USA	<i>C. glabrata</i>	0.12	1 (R)	0.25 (R)	D632E	WT	WT	WT
USA	<i>C. glabrata</i>	0.008	0.5 (R)	0.25 (R)	WT	WT	R665G	WT
USA	<i>C. glabrata</i>	0.03	2 (R)	1 (R)	S629P	WT	WT	WT
USA	<i>C. glabrata</i>	0.03	1 (R)	0.5 (R)	WT	WT	S663P	WT
USA	<i>C. glabrata</i>	0.06	0.25 (I)	0.5 (R)	WT	WT	WT	WT
USA	<i>C. glabrata</i>	0.06	4 (R)	4 (R)	WT	WT	S663P	WT
USA	<i>C. glabrata</i>	0.06	2 (R)	0.5 (R)	WT	WT	S663P	WT

^aDetermined according to the CLSI method. Categorical interpretations of susceptible (S), intermediate (I), and resistant (R) followed CLSI breakpoints (CLSI document M27M44S, 2022 [23]).

^bWT, wild type.

^cNT, Not tested.

posaconazole (Table 3). Given that echinocandins are commonly utilized for empirical therapy, it is notable that *Cryptococcus* spp. were intrinsically resistant to this class of agents (Table 3).

***In vitro* activity of manogepix and comparators against *Aspergillus* spp. and *Scedosporium* spp. isolates and determination of the wild-type manogepix MIC distribution against *Aspergillus* spp.** The most common *Aspergillus* species (containing 10 or more overall isolates) in the 2020 surveillance program that were tested against manogepix included the following four *Aspergillus* species complexes, in order of frequency: *A. fumigatus*, *Aspergillus* section Flavi, *Aspergillus* section Nigri, and *Aspergillus* section Terrei. The frequency and cumulative percent inhibition data for manogepix minimal effective concentration (MEC) values against *Aspergillus* spp. are presented in Tables 1 and 2.

Manogepix exhibited potent *in vitro* activity against all 4 *Aspergillus* species complexes shown in Table 1, with MEC₉₀ values of 0.015 to 0.06 mg/liter. The WT-UL for each species was 0.03 mg/liter for *Aspergillus* section Nigri (100.0% WT) and *Aspergillus* section Terrei (100.0% WT) and 0.06 mg/liter for both *A. fumigatus* (100.0% WT) and *Aspergillus* section Flavi (100.0% WT) (Tables 1 and 2). All (100.0%) of the *Aspergillus* spp. tested exhibited a WT manogepix phenotype (WT-UL, ≤0.06 mg/liter) (Table 1).

Manogepix (MEC₅₀/MEC₉₀, 0.015/0.03 mg/liter) and the echinocandin comparators anidulafungin and micafungin inhibited all 169 *A. fumigatus* isolates at ≤0.06 mg/liter (Table 5). These isolates displayed WT MEC/MIC results of 100.0%, 87.0%, and 96.4% for manogepix, itraconazole, and voriconazole (91.1% susceptible), respectively (Table 5). Of *A. fumigatus* isolates, 95.9% were inhibited by ≤0.5 mg/liter posaconazole (MIC₅₀/MIC₉₀, 0.25/0.5 mg/liter) (Table 5). Twenty-two isolates (13.0%) were NWT to itraconazole; 6 of these isolates were also NWT to voriconazole (MIC, ≥2 mg/liter). Of the 22 *A. fumigatus* isolates that displayed itraconazole MIC values greater than the CLSI ECV, 11 harbored *cyp51A* or *cyp51B* alterations (Table 6). The most common substitutions were *cyp51A* TR34/L98H (3 isolates) and *cyp51B* Q42L (3 isolates). Four *A. fumigatus* isolates harbored alterations in *cyp51A*, including 2 isolates with substitution I242V and 1 isolate each with substitutions N248K and G138C. Finally, 1 isolate carried multiple *cyp51A* alterations (F46Y, M172V, N248T, D255E, and E427K) (Table 6). The role of the less frequent alterations in *cyp51* in clinical resistance to the azoles is unclear, as several have been detected in azole-susceptible isolates. Among the itraconazole NWT isolates with *CYP* alterations, 6 were from the United States (10.2% of North American *A. fumigatus* isolates), 4 were from Europe (4.3% of European *A. fumigatus* isolates), and 1 was from the Asia-Western Pacific region (6.3% of Asia-Western Pacific isolates) (Table 6). The manogepix MEC values against the 11 isolates harboring alterations in *cyp51A* or *cyp51B* ranged from 0.008 to 0.06 mg/liter (all <WT-UL) (Table 6).

Manogepix (MEC₅₀/MEC₉₀, 0.015/0.06 mg/liter) inhibited all 24 *Aspergillus* section Flavi isolates at ≤0.06 mg/liter (100.0% WT) (Tables 1 and 5) and displayed similar activity as micafungin (MEC₅₀/MEC₉₀, 0.008/0.015 mg/liter) and anidulafungin (MEC₅₀/MEC₉₀, 0.008/0.015 mg/liter) (Table 5). All (100.0%) *Aspergillus* section Flavi isolates were WT to the mold-active azoles (Table 5).

Manogepix (MEC₅₀/MEC₉₀, 0.008/0.015 mg/liter) inhibited all 27 *Aspergillus* section Nigri isolates at ≤0.03 mg/liter (100.0% WT) (Tables 1 and 5) and displayed similar activity to micafungin (MEC₅₀/MEC₉₀, 0.008/0.03 mg/liter) and anidulafungin (MEC₅₀/MEC₉₀, 0.008/0.015 mg/liter). All but one *Aspergillus* section Nigri isolate was WT (96.3%) to the mold-active azoles (Table 5).

Manogepix (MEC₅₀/MEC₉₀, 0.008/0.015 mg/liter) inhibited all 14 *Aspergillus* section Terrei isolates at ≤0.03 mg/liter (100.0% WT) (Tables 1 and 5). This compound displayed similar activity to micafungin (MEC₅₀/MEC₉₀, 0.008/0.015 mg/liter) and anidulafungin (MEC₅₀/MEC₉₀, 0.015/0.03 mg/liter). All (100.0%) *Aspergillus* section Terrei isolates were WT to the mold-active azoles (Table 5).

Manogepix (MEC₅₀/MEC₉₀, 0.06/0.12 mg/liter; 100.0% inhibited at ≤0.5 mg/liter) was the most potent compound tested against a collection of 12 *Scedosporium* spp. isolates (Table 5). Corresponding echinocandin (anidulafungin and micafungin) and azole

TABLE 5 *In vitro* activities of manogepix and comparator antifungal agents tested against *Aspergillus* spp. and *Scedosporium* spp.

Organism (no. tested) and antifungal agent	MIC data (mg/liter)			CLSI CBP ^a			CLSI ECV ^b	
	MIC ₅₀ or MEC ₅₀	MIC ₉₀ or MEC ₉₀	Range	% S	% I/SDD	% R	% WT	% NWT
<i>A. fumigatus</i> (169)								
Manogepix	0.015	0.03	0.008–0.06				100.0	0.0
Anidulafungin	0.015	0.06	0.004–0.06					
Micafungin	0.008	0.015	≤0.002–0.03					
Itraconazole	1	2	0.25–>8				87.0	13.0
Posaconazole	0.25	0.5	0.06–8					
Voriconazole	0.5	0.5	0.12–8	91.1	5.3	3.6	96.4	3.6
Amphotericin B	1	2	0.5–4				98.8	1.2
<i>Aspergillus</i> section Flavi (24) ^c								
Manogepix	0.015	0.06	0.008–0.06				100.0	0.0
Anidulafungin	0.008	0.015	0.004–0.015					
Micafungin	0.008	0.015	≤0.002–0.015					
Itraconazole	0.5	1	0.5–1				100.0	0.0
Posaconazole	0.5	0.5	0.25–0.5				100.0	0.0
Voriconazole	0.5	1	0.25–1				100.0	0.0
Amphotericin B	2	2	1–>4				95.8	4.2
<i>Aspergillus</i> section Nigri (27) ^d								
Manogepix	0.008	0.015	0.004–0.03				100.0	0.0
Anidulafungin	0.008	0.015	0.004–0.03					
Micafungin	0.008	0.03	≤0.002–0.03					
Itraconazole	1	4	1–8				96.3	3.7
Posaconazole	0.5	1	0.25–1				100.0	0.0
Voriconazole	0.5	2	0.5–2				100.0	0.0
Amphotericin B	0.5	1	0.5–2				100.0	0.0
<i>Aspergillus</i> section Terrei (14) ^e								
Manogepix	0.008	0.015	0.004–0.03				100.0	0.0
Anidulafungin	0.015	0.03	≤0.002–0.06					
Micafungin	0.008	0.015	0.004–0.015					
Itraconazole	0.5	1	0.25–1				100.0	0.0
Posaconazole	0.25	0.5	0.12–0.5				100.0	0.0
Voriconazole	0.5	0.5	0.12–1				100.0	0.0
Amphotericin B	2	4	1–4				100.0	0.0
<i>Scedosporium</i> spp. (12) ^f								
Manogepix	0.06	0.12	0.03–0.5					
Anidulafungin	4	>4	4–>4					
Micafungin	0.5	>4	0.25–>4					
Itraconazole	>8	>8	2–>8					
Posaconazole	>8	>8	1–>8					
Voriconazole	1	1	0.25–1					
Amphotericin B	>4	>4	1–>4					

^aCLSI breakpoint criteria. Susceptible (S), intermediate/susceptible dose-dependent (I/SDD), resistant (R).

^bECV, epidemiological cutoff value; WT, wild type; NWT, non-wild type. The WT-UL was used in place of ECV for manogepix (see Table 2).

^cOrganisms (number of isolates) included *Aspergillus flavus* species complex (22) and *A. parasiticus* (2).

^dOrganisms (number of isolates) included *Aspergillus niger* (13) and *A. niger* species complex (14).

^eOrganisms (number of isolates) included *Aspergillus hortai* (1), *A. terreus* (6), and *A. terreus* species complex (7).

^fOrganisms (number of isolates) included *Scedosporium apiospermum/Scedosporium boydii* (9) and *S. aurantiacum* (3).

(itraconazole, posaconazole, and voriconazole) MIC₅₀/MIC₉₀ values were 4 to >4/>4 mg/liter and 1 to >8/1 to >8 mg/liter, respectively (Table 5).

***In vitro* activities of manogepix against rare species of *Candida*, non-*Candida* yeasts, and rare molds.** Manogepix MIC and MEC values obtained for 24 other *Candida* spp., 26 other yeasts, 12 other *Aspergillus* spp., and 52 other mold isolates are listed in Table 1 and Tables S1 and S2. Manogepix was active against many uncommon *Candida* spp. isolates, including *Candida bracarensis* (MIC range, 0.004 to 0.008 mg/liter), *Candida duobushaemulonii* (MIC, ≤0.002 mg/liter), *Candida fermentati* (MIC, 0.03 mg/liter), *Candida guilliermondii* (MIC range, 0.004 to 0.015 mg/liter), *Candida haemulonii* (MIC, ≤0.002 mg/liter), *Candida nivariensis*

TABLE 6 Summary of CYP alterations detected among non-wild-type *Aspergillus* spp. isolates in the 2020 international surveillance program

Country	Organism	MIC data (mg/liter) ^a				CYP alteration(s)	
		Manogepix	Voriconazole	Itraconazole	Posaconazole	CYP51A	CYP51B
USA	<i>A. fumigatus</i>	0.015	0.5 (WT)	2 (NWT)	0.25 (WT)	I242V	WT
USA	<i>A. fumigatus</i>	0.06	1 (WT)	2 (NWT)	0.5 (WT)	WT	Q42L
USA	<i>A. fumigatus</i>	0.015	0.5 (WT)	2 (NWT)	0.25 (WT)	WT	Q42L
USA	<i>A. fumigatus</i>	0.03	0.5 (WT)	2 (NWT)	0.5 (WT)	N248K	WT
USA	<i>A. fumigatus</i>	0.015	0.5 (WT)	2 (NWT)	0.5 (WT)	F46Y, M172V, N248T, D255E, E427K	WT
France	<i>A. fumigatus</i>	0.06	1 (WT)	4 (NWT)	1 (NWT)	WT	Q42L
New Zealand	<i>A. fumigatus</i>	0.03	8 (NWT)	>8 (NWT)	8 (NWT)	G138C	WT
UK	<i>A. fumigatus</i>	0.015	2 (NWT)	4 (NWT)	1 (NWT)	L98H, TR34	WT
UK	<i>A. fumigatus</i>	0.008	2 (NWT)	4 (NWT)	0.5 (WT)	L98H, TR34	WT
UK	<i>A. fumigatus</i>	0.008	2 (NWT)	8 (NWT)	1 (NWT)	L98H, TR34	WT
USA	<i>A. fumigatus</i>	0.015	0.5 (WT)	2 (NWT)	0.25 (WT)	I242V	WT

^aCategorical interpretations of non-wild type (NWT) and wild type (WT) are according to ECVs from CLSI document M57 (24). The ECV for posaconazole was 0.5 mg/liter.

(MIC, 0.004 mg/liter), *Candida pelliculosa* (MIC, \leq 0.002 mg/liter), *Candida rugosa* (MIC range, 0.008 to 0.03 mg/liter), *Candida spencermartinsiae* (MIC, 0.008 mg/liter), and *Candida utilis* (MIC, \leq 0.002 mg/liter) (Table S1). Manogepix was also active against infrequently encountered non-*Candida* yeasts, including *Saprochaete clavata* (MIC range, 0.03 to 0.06 mg/liter), *Kodamaea ohmeri* (MIC, 0.008 mg/liter), *Magnusiomyces capitatus* (*Saprochaete capitata*; MIC, 0.015 mg/liter), *Rhodotorula mucilaginosa* (MIC range, 0.03 to 0.06 mg/liter), *Saccharomyces cerevisiae* (MIC range, 0.008 to 0.015 mg/liter), and *Yarrowia lipolytica* (MIC, 0.03 mg/liter) (Table S1).

Notably, manogepix was active against many less common and frequently antifungal-resistant fungi (to azole and/or echinocandin), including *Aspergillus nidulans* (MEC range, 0.008 to 0.015 mg/liter), *Aspergillus sclerotiorum* (MEC, 0.015 mg/liter), *Aspergillus ustus* species complex (MEC, 0.008 mg/liter), *Aspergillus versicolor* (MEC, 0.015 mg/liter), *Exophiala dermatitidis* (MEC, \leq 0.002 mg/liter), *Fusarium incarnatum-equiseti* species complex (MEC, \leq 0.002 mg/liter), *Fusarium solani* species complex (MEC range, 0.004 to 0.015 mg/liter), *Gibberella fujikuroi* species complex (MEC, 0.008 to 0.015 mg/liter), *Lomentospora prolificans* (MEC range, 0.03 to 0.06 mg/liter), *Purpureocillium lilacinum* (MEC range, \leq 0.002 to 0.008 mg/liter), *Paecilomyces variotii* (MEC range, 0.004 to 0.008 mg/liter), *Penicillium citrinum* (MEC, 0.008 mg/liter), *Penicillium onobense* (MEC, 0.008 mg/liter), *Rasamsonia argillacea* species complex (MEC range, \leq 0.002 to 0.004 mg/liter), and *Scopulariopsis brevicaulis* (MEC, 0.008 mg/liter). Fungal species with increased MICs to manogepix included *Candida inconspicua* (MIC range, 0.5 to 2 mg/liter), *Cunninghamella* sp. (MEC, 8 mg/liter), *Lichtheimia corymbifera* (MEC, 4 mg/liter), *Lichtheimia* sp. (MEC, 4 mg/liter), *Mucor circinelloides* (MEC range, 0.25 to 1 mg/liter), *Mucor indicus* (MEC, 1 mg/liter), *Rhizopus microsporus* group (MEC range, 2 to >8 mg/liter), and *Rhizopus oryzae* species complex (MEC range, 4 to >8 mg/liter) (Tables S1 and S2).

DISCUSSION

Recent antifungal surveillance programs have documented the prominent roles of *Aspergillus*, *Candida*, and *Cryptococcus* as leading IFI pathogens (1, 2, 12, 20, 25). Although antifungal resistance is a global concern (3, 4), fortunately at present, most clinical isolates of these pathogens remain susceptible or WT to azoles, echinocandins, and polyenes (12). This relatively good news is countered by some less common species of *Candida* and *Aspergillus* (e.g., *C. auris* and *A. lentulus*, respectively), non-*Candida* and non-*Cryptococcus* yeasts, and non-*Aspergillus* molds, many of which express intrinsic or acquired resistance to available first-line agents (1–5, 12, 26). Notably, the novel antifungal manogepix exhibits potent antifungal activity against these fungal pathogens (13).

The data presented here expand upon our earlier observations (12, 20) and provide a robust estimate of the WT MIC and MEC distributions of manogepix for 7 species of *Candida* and 4 species of *Aspergillus* (Table 2). Although multicenter studies involving

larger numbers of isolates of each species will be required to establish both ECVs and clinical breakpoints for manogepix, we suggest that the WT-UL values should be ≤ 0.015 mg/liter for *C. dubliniensis* (99.4% of 154 isolates), ≤ 0.03 mg/liter for *C. albicans* (99.9% of 1,352 isolates) and *C. parapsilosis* (98.8% of 756 isolates), ≤ 0.06 mg/liter for *C. tropicalis* (99.6% of 515 isolates), ≤ 0.12 mg/liter for *C. lusitaniae* (97.2% of 107 isolates), ≤ 0.25 mg/liter for *C. glabrata* (100.0% of 1,039 isolates), ≤ 1 mg/liter for *C. kefir* (100.0% of 51 isolates), ≤ 0.03 mg/liter for *A. nigri* (100.0% of 117 isolates) and *A. terreus* (100.0% of 43 isolates), and ≤ 0.06 mg/liter for *A. fumigatus* (100.0% of 748 isolates) and *A. flavus* SC (100.0% of 115 isolates) (Table 2). These values are comparable to the WT-UL values determined for these species and species groups by the Danish nationwide surveillance program, which reported manogepix species-specific modal MIC values obtained with the EUCAST method (8, 15–17). Thus, both CLSI and EUCAST BMD methods have provided comparable estimates of the *in vitro* activity of manogepix and documented the sustained activity of this agent against yeasts and molds over time.

In the 2020 surveillance program, we confirmed and extended our previous findings regarding the high potency and broad spectrum of manogepix activity against common species of *Candida* and *Aspergillus* (Tables 1 and 2), as well as against uncommon species of *Candida*, non-*Candida* yeasts, rare species of *Aspergillus*, and other rare molds (Table 1; see also Tables S1 and S2 in the supplemental material). Given that the major concerns regarding antifungal resistance center on the echinocandins for *Candida* spp. and the triazoles for *Aspergillus fumigatus*, we utilized whole-genome sequencing to identify *FKS* mutations in *Candida* spp. expressing resistance to echinocandins and *cyp51* mutations in *A. fumigatus* isolates exhibiting resistance to the mold-active triazoles (Tables 4 and 6). As demonstrated previously, isolates harboring these important resistance mechanisms were all WT for manogepix (8, 12, 15–17, 20). A recent study (27) demonstrated that enhanced efflux expression in *Candida albicans* and *C. parapsilosis* mutants was responsible for decreased manogepix susceptibility.

This international surveillance study demonstrated and verified the potent *in vitro* activity of manogepix against contemporary fungal isolates, including echinocandin- and azole-resistant strains of *Candida* and *Aspergillus* spp. We have expanded the MIC database for manogepix against a broad range of common and uncommon IFI pathogens, and we have shown consistent susceptibility results for manogepix against *Candida* and *Aspergillus* species over time. The broad spectrum of manogepix is noteworthy for its activity against many less common and often antifungal-resistant yeast and mold strains. Continued development of the manogepix prodrug (fosmanogepix) for the treatment of invasive fungal infections, including multidrug-resistant strains, is warranted.

MATERIALS AND METHODS

Organisms. A total of 1,435 nonduplicate fungal clinical isolates were collected in the SENTRY Surveillance Program during 2020 from 73 medical centers located in North America, Europe, the Asia-Pacific region, and Latin America. The fungal isolates were recovered from patients with bloodstream infections (BSIs; $n = 693$), respiratory tract infections (RTIs; $n = 253$), skin and skin structure infections (SSSIs; $n = 100$), urinary tract infections (UTIs; $n = 45$), intra-abdominal infections (IAIs; $n = 20$), and infections in other sites ($n = 324$).

Fungal identification methods. Yeast isolates were subcultured on HardyCHROM agar medium (Hardy Diagnostics, Santa Maria, CA, USA) upon arrival to confirm culture purity for *Candida* spp. isolates and submitted to matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) using the MALDI Biotyper (Bruker Daltonics, Billerica, MA, USA). Any yeast isolates not identified by this process were identified using sequencing-based methods for the internal transcribed spacer (ITS) region, 28S ribosomal subunit, or intergenic spacer 1 for *Trichosporon* spp. (18, 28–30).

Mold isolates were identified by DNA sequencing when an acceptable identification was not achieved by MALDI-TOF MS. For all isolates, 28S was sequenced and 1 of the following genes was analyzed: β -tubulin for *Aspergillus* spp., translation elongation factor (TEF) for *Fusarium* spp., or ITSs for all other species of filamentous fungi (18, 28–30).

Nucleotide sequences were analyzed using Lasergene software (DNASar, Madison, WI, USA) and compared to available sequences using BLAST (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>). TEF sequences were analyzed using the *Fusarium* multilocus sequence typing database (<https://fusarium.mycobank.org/>).

Susceptibility testing. Fungal susceptibility testing was conducted according to broth microdilution (BMD) methods as described by Clinical and Laboratory Standards Institute (CLSI) documents M27 (31)

and M38 (32). Manogepix MIC and MEC values were determined visually after incubation at 35°C for 24 h (*Candida* spp. MIC) or 48 to 72 h (*Aspergillus* spp. [48-h MEC], other molds [*Scedosporium* spp. 72-h MEC], other yeasts [48-h MIC], and *C. neoformans* [72-h MIC]).

Yeast MIC endpoints were read as the lowest drug concentration that produced a significant decrease ($\geq 50\%$ inhibition) of growth below the control for manogepix (23, 31, 33), fluconazole, posaconazole, voriconazole, and the echinocandins, or the concentration preventing any discernible growth for amphotericin B (23, 31). Mold MIC endpoints were read as the lowest drug concentration preventing any discernible growth (amphotericin B, posaconazole, voriconazole, and itraconazole) (32, 34). MEC endpoints (morphology change from flocculent growth to small, matted colonies) were read for manogepix and the echinocandins (18, 32, 34).

Susceptibility interpretive criteria (CBPs and ECVs, where available) were those published in CLSI documents M27 (31), M38 (32), M575 (24), M27M445 (23), and M38M515 (34). Breakpoints for *C. auris* and amphotericin B, fluconazole, anidulafungin, and micafungin originated from published CDC tentative MIC breakpoints (<https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.html>).

CBPs and ECVs have not yet been determined for manogepix against any fungal species. For comparison, previously published manogepix MIC distribution data from the SENTRY surveillance performed in 2017 (20) and 2018–2019 (12) plus the present (2020) survey results were employed to generate a wild-type upper limit (WT-UL; two 2-fold dilutions higher than the modal MIC value of each MIC distribution). This WT-UL was used as the cutoff value to define wild type ($\text{MIC} \leq \text{WT-UL}$) and non-WT ($\text{MIC} > \text{WT-UL}$) populations for manogepix and each species (12, 15–17, 20).

Quality control (QC) was conducted according to CLSI documents M27 (31) and M38 (32) using *Candida parapsilosis* ATCC 22019, *Aspergillus flavus* ATCC 204304, and *Aspergillus fumigatus* ATCC MYA-3626. All MIC and MEC values for manogepix against *C. parapsilosis* ATCC 22019, *A. flavus* ATCC 204304, and *A. fumigatus* ATCC MYA-3626 were within QC ranges published in CLSI documents M27M445 (23) and M38M515 (30).

Resistance mechanisms. *Candida* spp. isolates showing echinocandin MIC values above the ECV as well as *Aspergillus fumigatus* isolates displaying azole MIC values above the ECV were subjected to whole-genome sequencing (35). Total genomic DNA was used as input material for library construction prepared using the Illumina DNA library construction protocol and index kit (Illumina, San Diego, CA, USA) following the manufacturer's instructions. Sequencing was performed on a NextSeq 1000 sequencer (Illumina). Reads were trimmed with Sickle version 1.33 (36) and error corrected using BayesHammer from SPAdes 3.11.1 (37). Each sample was assembled using a reference-guided assembly in DNASTAR SeqMan NGen v.16.0.0 (Madison, WI, USA). DNA regions encoding the FKS hot spots in *Candida* spp. and CYP regions in *A. fumigatus* were compared to available sequences in the literature.

Data availability. Data will be made available upon reasonable request.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

SUPPLEMENTAL FILE 1, PDF file, 0.2 MB.

ACKNOWLEDGMENTS

JMI Laboratories has contracted to perform services in 2020 for Achaogen, Inc., Albany College of Pharmacy and Health Sciences, Allegra Therapeutics, Allergan, AmpliPhi Biosciences Corp., Amicrobe Advanced Biomaterials, Amplyx, Antabio, American Proficiency Institute, Arietis Corp., Arixia Pharmaceuticals, Inc., Astellas Pharma Inc., Athelas, Basilea Pharmaceutica Ltd., Bayer AG, Becton, Dickinson and Company, bioMérieux SA, Boston Pharmaceuticals, Bugworks Research Inc., CEM-102 Pharmaceuticals, Cepheid, Cidara Therapeutics, Inc., CorMedix Inc., DePuy Synthes, Destiny Pharma, Discuva Ltd., Dr. Falk Pharma GmbH, Emery Pharma, Entasis Therapeutics, Eurofarma Laboratorios SA, U.S. Food and Drug Administration, Fox Chase Chemical Diversity Center, Inc., Gateway Pharmaceutical LLC, GenePOC Inc., Geom Therapeutics, Inc., GlaxoSmithKline plc, Harvard University, Helperby, HiMedia Laboratories, F. Hoffmann-La Roche Ltd., ICON plc, Idorsia Pharmaceuticals Ltd., Iterum Therapeutics plc, Laboratory Specialists, Inc., Melinta Therapeutics, Inc., Merck & Co., Inc., Microchem Laboratory, Micromyx, MicuRx Pharmaceuticals, Inc., Mutabilis Co., Nabriva Therapeutics plc, NAEJA-RGM, Novartis AG, Oxoid Ltd., Paratek Pharmaceuticals, Inc., Pfizer, Inc., Polyphor Ltd., Pharmaceutical Product Development, LLC, Prokaryotics Inc., Qpex Biopharma, Inc., Roivant Sciences, Ltd., Safeguard Biosystems, Scynexis, Inc., SeLux Diagnostics, Inc., Shionogi and Co., Ltd., SinSa Labs, Spero Therapeutics, Summit Pharmaceuticals International Corp., Synlogic, T2 Biosystems, Inc., Taisho Pharmaceutical Co., Ltd., TenNor Therapeutics Ltd., Tetrphase Pharmaceuticals, Theravance Biopharma, University of Colorado, University of Southern California San Diego, University of North Texas Health Science Center, VenatoRx Pharmaceuticals, Inc., Viosera

Therapeutics, Vyome Therapeutics Inc., Wockhardt, Yukon Pharmaceuticals, Inc., Zai Lab, and Zavante Therapeutics, Inc. There are no speakers' bureaus or stock options to declare.

The studies were performed by JMI Laboratories and supported by Pfizer, Inc.; this support included funding for services related to preparing the manuscript.

REFERENCES

- Almeida F, Rodrigues ML, Coelho C. 2019. The still underestimated problem of fungal diseases worldwide. *Front Microbiol* 10:214. <https://doi.org/10.3389/fmicb.2019.00214>.
- Bongomin F, Gago S, Oladele RO, Denning DW. 2017. Global and multi-national prevalence of fungal diseases—estimate precision. *J Fungi* 3:57. <https://doi.org/10.3390/jof3040057>.
- Arastehfar A, Lass-Flörl C, Garcia-Rubio R, Daneshnia F, Ilkit M, Boekhout T, Gabaldon T, Perlin DS. 2020. The quiet and underappreciated rise of drug-resistant invasive fungal pathogens. *J Fungi* 6:138. <https://doi.org/10.3390/jof6030138>.
- Araujo R, Oliveira M, Amorim A, Sampaio-Maia B. 2015. Unpredictable susceptibility of emerging clinical moulds to tri-azoles: review of the literature and upcoming challenges for mould identification. *Eur J Clin Microbiol Infect Dis* 34:1289–1301. <https://doi.org/10.1007/s10096-015-2374-1>.
- Friedman DZP, Schwartz IS. 2019. Emerging fungal infections: new patients, new patterns, and new pathogens. *J Fungi (Basel)* 5:67. <https://doi.org/10.3390/jof5030067>.
- Thornton CR. 2020. Detection of the 'big five' mold killers of humans: *Aspergillus*, *Fusarium*, *Lomentospora*, *Scedosporium* and *Mucormycetes*. *Adv Appl Microbiol* 110:1–61. <https://doi.org/10.1016/bs.aambs.2019.10.003>.
- Jacobs S, Zagaliotis P, Walsh T. 2021. Novel antifungal agents in clinical trials. *F1000Res* 10:507. <https://doi.org/10.12688/f1000research.28327.1>.
- Jorgensen K, Astvad K, Arendrup M. 2020. *In vitro* activity of manogepix (APX001A) and comparators against contemporary molds; MEC comparison and preliminary experience with colorimetric MIC determination. *Antimicrob Agents Chemother* 64:e00730-20. <https://doi.org/10.1128/AAC.00730-20>.
- McCarty T, Pappas P. 2021. Antifungal pipeline. *Front Cell Infect Microbiol* 11:732223. <https://doi.org/10.3389/fcimb.2021.732223>.
- Rauseo AM, Coler-Reilly A, Larson L, Spec A. 2020. Hope on the horizon: novel fungal treatments in development. *Open Forum Infect Dis* 7: ofaa016. <https://doi.org/10.1093/ofid/ofaa016>.
- Seiler G, Ostrosky-Zeichner L. 2021. Investigational agents for the treatment of resistant yeasts and molds. *Curr Fungal Infect Rep* 15:104–115. <https://doi.org/10.1007/s12281-021-00419-5>.
- Pfaller MA, Huband MD, Flamm RK, Bien PA, Castanheira M. 2021. Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance program (2018–2019). *J Glob Antimicrob Resist* 26:117–127. <https://doi.org/10.1016/j.jgar.2021.04.012>.
- Shaw KJ, Ibrahim AS. 2020. Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections. *J Fungi* 6:239. <https://doi.org/10.3390/jof6040239>.
- Watanabe NA, Miyazaki M, Horii T, Sagane K, Tsukahara K, Hata K. 2012. E1210, a new broad-spectrum antifungal, suppresses *Candida albicans* hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis. *Antimicrob Agents Chemother* 56:960–971. <https://doi.org/10.1128/AAC.00731-11>.
- Arendrup MC, Prakash A, Meletiadis J, Sharma C, Chowdhary A. 2017. Comparison of EUCAST and CLSI reference microdilution MICs of eight antifungal compounds for *Candida auris* and associated tentative epidemiological cutoff values. *Antimicrob Agents Chemother* 61:e00485-17. <https://doi.org/10.1128/AAC.00485-17>.
- Arendrup M, Jorgensen K. 2020. Manogepix (APX001A) displays potent *in vitro* activity against human pathogenic yeast, but with an unexpected correlation to fluconazole MICs. *Antimicrob Agents Chemother* 64:e00429-20. <https://doi.org/10.1128/AAC.00429-20>.
- Arendrup M, Chowdhary A, Jorgensen K, Meletiadis J. 2020. Manogepix (APX001A) *in vitro* activity against *Candida auris*: head-to-head comparison of EUCAST and CLSI MICs. *Antimicrob Agents Chemother* 64:e00656-20. <https://doi.org/10.1128/AAC.00656-20>.
- Castanheira M, Duncanson FP, Diekema DJ, Guarro J, Jones RN, Pfaller MA. 2012. Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against *Fusarium* and *Scedosporium* species identified using molecular methods. *Antimicrob Agents Chemother* 56:352–357. <https://doi.org/10.1128/AAC.05414-11>.
- Hata K, Horii T, Miyazaki M, Watanabe NA, Okubo M, Sonoda J, Nakamoto K, Tanaka K, Shirotori S, Murai N, Inoue S, Matsukura M, Abe S, Yoshimatsu K, Asada M. 2011. Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis. *Antimicrob Agents Chemother* 55:4543–4551. <https://doi.org/10.1128/AAC.00366-11>.
- Pfaller MA, Huband MD, Flamm RK, Bien PA, Castanheira M. 2019. *In vitro* activity of APX001A (manogepix) and comparator agents against 1,706 fungal isolates collected during an international surveillance program (2017). *Antimicrob Agents Chemother* 63:e00840-19. <https://doi.org/10.1128/AAC.00840-19>.
- Rivero-Menendez O, Cuenca-Estrella M, Alastruey-Izquierdo A. 2019. *In vitro* activity of APX001A against rare moulds using EUCAST and CLSI methodologies. *J Antimicrob Chemother* 74:1295–1299. <https://doi.org/10.1093/jac/dkz022>.
- Wiederhold NP, Najvar LK, Fothergill AW, McCarthy DI, Bocanegra R, Olivo M, Kirkpatrick WR, Everson MP, Duncanson FP, Patterson TF. 2015. The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant *Candida albicans*. *Antimicrob Agents Chemother* 59:690–692. <https://doi.org/10.1128/AAC.03944-14>.
- Clinical and Laboratory Standards Institute. 2022. Performance standards for antifungal susceptibility testing of yeasts. CLSI M27M44S. Clinical and Laboratory Standards Institute, Wayne, PA. <https://clsi.org/standards/products/microbiology/documents/m27m44s/>.
- Clinical and Laboratory Standards Institute. 2016. Principles and procedures for the development of epidemiological cutoff values for antifungal susceptibility testing, 1st ed. CLSI M57S. Clinical and Laboratory Standards Institute, Wayne, PA.
- Astvad KMT, Johansen HK, Roder BL, Rosenvinge FS, Knudsen JD, Lemming L, Schonheyder HC, Hare RK, Kristensen L, Nielsen L, Gertsen JB, Dzajic E, Pedersen M, Ostergard C, Olesen B, Sondergaard TS, Arendrup MC. 2018. Update from a 12-year nationwide fungemia surveillance: increasing intrinsic and acquired resistance causes concern. *J Clin Microbiol* 56:e01564-17. <https://doi.org/10.1128/JCM.01564-17>.
- Arikan-Akdagli S, Ghannoum M, Meis JF. 2018. Antifungal resistance: specific focus on multidrug resistance in *Candida auris* and secondary azole resistance in *Aspergillus fumigatus*. *J Fungi* 4:129. <https://doi.org/10.3390/jof4040129>.
- Liston S, Whitesell L, Kapoor M, Shaw K, Cowen L. 2020. Enhanced efflux pump expression in *Candida* mutants results in decreased manogepix susceptibility. *Antimicrob Agents Chemother* 64:e00261-20. <https://doi.org/10.1128/AAC.00261-20>.
- Pfaller MA. 2015. Invasive fungal infections and approaches to their diagnosis, p 219–287. *In* Sails A, Tang Y (ed), *Methods in microbiology*, vol 72. Academic Press, Oxford, United Kingdom.
- Pfaller MA, Woosley LN, Messer SA, Jones RN, Castanheira M. 2012. Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance program. *Mycopathologia* 174:259–271. <https://doi.org/10.1007/s11046-012-9551-x>.
- Pfaller MA, Rhomberg PR, Wiederhold NP, Gibas C, Sanders C, Fan H, Mele J, Kovanda LL, Castanheira M. 2018. *In vitro* activity of isavuconazole versus opportunistic fungal pathogens from two mycology reference laboratories. *Antimicrob Agents Chemother* 62:e01230-18. <https://doi.org/10.1128/AAC.01230-18>.
- Clinical and Laboratory Standards Institute. 2017. Reference method for broth dilution antifungal susceptibility testing of yeasts. CLSI M27Ed4. Clinical and Laboratory Standards Institute, Wayne, PA.
- Clinical and Laboratory Standards Institute. 2018. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, 3rd ed. CLSI M38Ed3. Clinical and Laboratory Standards Institute, Wayne, PA.

33. Pfaller MA, Watanabe N, Castanheira M, Messer SA, Jones RN. 2011. Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus *Candida*: comparison of CLSI and EUCAST methods. *J Antimicrob Chemother* 66:2581–2584. <https://doi.org/10.1093/jac/dkr342>.
34. Clinical and Laboratory Standards Institute. 2022. Performance standards for antifungal susceptibility testing of filamentous fungi. CLSI M38M51S. Clinical and Laboratory Standards Institute, Wayne, PA. https://clsi.org/media/retijtfi/m38m51sed3e_sample.pdf.
35. Castanheira M, Deshpande LM, Davis AP, Rhomberg PR, Pfaller MA. 2017. Monitoring antifungal resistance in a global collection of invasive yeasts and molds: application of CLSI epidemiological cutoff values and whole genome sequencing analysis for detection of azole resistance in *Candida albicans*. *Antimicrob Agents Chemother* 61:e00906-17. <https://doi.org/10.1128/AAC.00906-17>.
36. Joshi N, Fass JN. 2011. Sickle: a sliding-window, adaptive, quality-based trimming tool for FastQ files, version 1.33. <https://github.com/najoshi/sickle>. Accessed 30 September 2019.
37. Nurk S, Bankevich A, Antipov D, Gurevich AA, Korobeynikov A, Lapidus A, Prjibelski AD, Pyshkin A, Sirotkin A, Sirotkin Y, Stepanauskas R, Clingenpeel SR, Woyke T, McLean JS, Lasken R, Tesler G, Alekseyev MA, Pevzner PA. 2013. Assembling single-cell genomes and mini-metagenomes from chimeric MDA products. *J Comput Biol* 20:714–737. <https://doi.org/10.1089/cmb.2013.0084>.